Dmitry Balyasny’s Bicara Therapeutics BCAX Stock Holding History

Dmitry Balyasny’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,797	Closed	-$434K	–	3594
2026 Q1	$434K	Buy	+21,797	New	+$375K	﹤0.01%	2425

Other funds holding BCAX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RTM

Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dmitry Balyasny's BCAX Position: Q2 2026 in Review

Dmitry Balyasny sold out of Bicara Therapeutics (BCAX) in Q2 2026, closing a stake of 21,797 shares — an estimated $434K sold.

Dmitry Balyasny first reported a position in BCAX in Q1 2026 and held it in 1 quarter. The position peaked at $434K in Q1 2026. 169 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

Dmitry Balyasny reported no remaining Bicara Therapeutics position as of Q2 2026 after selling out during the quarter.
Dmitry Balyasny sold 21,797 Bicara Therapeutics shares in Q2 2026, an estimated $434K.
Dmitry Balyasny first reported a position in Bicara Therapeutics in Q1 2026 and held it in 1 quarter.
Dmitry Balyasny's Bicara Therapeutics position peaked at $434K in Q1 2026.
169 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.